Applied Therapeutics
AcquiredNew York, US · Founded 2016 · Delaware corporation · 3 known investors
Find your way into Applied Therapeutics
29 people in our graph share verified history with the Applied Therapeutics team — schools, employers, funds. One of them is your warm intro.
Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Also known as Applied Therapeutics, Inc.
Founders & leadership
Applied Therapeutics was founded in 2016 by Shoshana Shendelman.
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$189.2M disclosed across 6 rounds · 2017–2024
▶$100MraisedMar 2024 · 31 investors · BiotechnologyRule 506(b)
- Riccardo PerfettiExecutive Officer
- Adam HansardExecutive Officer
- Stacy J. KanterDirector
- Catherine ThorpeExecutive Officer
- Les FuntleyderExecutive Officer, Director
- Joel S. MarcusDirector
- Shoshana ShendelmanExecutive Officer, Director
- Teena LernerDirector
- Jay SkylerDirector
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $7.5M
- Placement agents
- Robert W. Baird & Co. Inc., RBC Capital Markets, LLC, Leerink Partners LLC, UBS Securities LLC
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedMay 2023 · 19 investors · BiotechnologyRule 506(b)
- Stacy J. KanterDirector
- Joel S. MarcusDirector
- Adam HansardExecutive Officer
- Shoshana ShendelmanExecutive Officer, Director
- Jay SkylerDirector
- Les FuntleyderDirector
- Riccardo PerfettiExecutive Officer
- Teena LernerDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $2.1M
- Placement agents
- UBS Securities LLC, SVB Securities LLC
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedNov 2019 · 12 investors · BiotechnologyRule 506(b)
- Joel S. MarcusDirector
- Stacy J. KanterDirector
- Les FuntleyderDirector
- Mark VignolaExecutive Officer
- Riccardo PerfettiExecutive Officer
- Shoshana ShendelmanExecutive Officer, Director
- Teena LernerDirector
- Jay SkylerDirector
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1.3M
- Placement agents
- Collage Partners, a division of CIM Securities LLC
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$27.2MraisedNov 2018 · 37 investors · BiotechnologyRule 506(b)
- Shoshana ShendelmanExecutive Officer, Director
- Franklin BergerDirector
- Les FuntleyderDirector
- Teena LernerDirector
- Joel MarcusDirector
- Offering amount
- $56.6M
- Amount sold
- $27.2M
- Sales commissions
- $521.7K
- Placement agents
- CIM Securities, LLC
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$6MraisedFeb 2018 · 23 investors · Other Health CareRule 506(b)
- Les FuntleyderDirector
- Joel MarcusDirector
- Shoshana ShendelmanExecutive Officer, Director
- Franklin BergerDirector
- Teena LernerDirector
- Offering amount
- $6M
- Amount sold
- $6M
- Sales commissions
- $420K
- Placement agents
- a division of CIM Securities, LLC
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$6.1MraisedFeb 2017 · 26 investors · Other Health CareRule 506(b)
- Shoshana ShendelmanExecutive Officer, Director
- Les FuntleyderDirector
- Offering amount
- $7M
- Amount sold
- $6.1M
- Sales commissions
- $560K
- Placement agents
- a division of CIM Securities, LLC
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Applied Therapeutics is a biopharmaceutical company focused on creating treatments for rare diseases with high unmet medical need. Its lead investigational product is govorestat, an aldose reductase inhibitor developed for Classical Galactosemia and CMT-SORD, where the mechanism targets galactitol reduction and sorbitol-related pathways respectively. The company describes an approach of targeting molecules and pathways with established roles in disease biology while making use of FDA guidance on biomarkers and established clinical endpoints, with the stated aim of shortening the path from clinical development to approval.
Govorestat has been evaluated in adult Phase 1/2 safety, pharmacokinetic and pharmacodynamic studies and in the pediatric ACTION-Galactosemia Kids study, both published in the Journal of Clinical Pharmacology in 2024. The FDA reviewed a New Drug Application for govorestat in Classical Galactosemia and issued a Complete Response Letter in November 2024, indicating additional information was required before approval; the company stated the decision was not based on new safety concerns and that it would work with the FDA on next steps. In April 2026 the company announced it was discontinuing all active Applied-sponsored clinical studies of govorestat and ending its Expanded Access Program in order to evaluate new development strategies, stating the decision reflected program planning considerations rather than new safety findings, while continuing to review clinical, biomarker and safety data and engage with regulators on Classical Galactosemia and CMT-SORD.
Latest developments
In November 2025 the company announced corporate updates; in December 2025 it announced that Cycle Pharmaceuticals would acquire Applied Therapeutics; and in January 2026 it issued a letter to stockholders recommending tender of shares following an extension of the offer expiration. Applied Therapeutics and Cycle Pharmaceuticals are described as separate companies owned by Cycle Group Holdings, with Applied Therapeutics retaining responsibility for govorestat development, clinical programs and regulatory interactions. On April 17, 2026 the company announced discontinuation of all active Applied-sponsored govorestat clinical studies and the end of its Expanded Access Program.
▸Full profile — technology, go-to-market, risks & controversies
Technology
The company's lead asset, govorestat, is an aldose reductase inhibitor. In Classical Galactosemia the mechanism is described as reduction of galactitol, and in CMT-SORD it acts on sorbitol-related pathways. Company communications note that the medication gradually leaves the body over several days after discontinuation, with no known physical dependence, and that related biomarkers may gradually return toward pre-treatment levels if therapy stops. Development strategy relies on biomarkers supported by FDA guidance alongside established clinical endpoints.
Go-to-market
Patients with rare diseases, specifically those with Classical Galactosemia and CMT-SORD, together with their caregivers and treating physicians.
Risks & controversies
The FDA issued a Complete Response Letter for the govorestat New Drug Application in Classical Galactosemia in November 2024, stating that additional information was needed before approval; the company said the decision was not based on new safety concerns. In April 2026 the company discontinued all active Applied-sponsored clinical studies of govorestat and terminated its Expanded Access Program, removing that route of access for patients, and stated it could not guarantee govorestat access outside approved programs.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 1
by search overlapCompanies competing with Applied Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 5
launches, deals, and filingsThe company discontinued all active Applied-sponsored clinical studies of govorestat and ended its Expanded Access Program to focus on evaluating new development strategies, stating the decision was based on program planning considerations rather than new or emerging safety findings.
Announcement that Cycle Pharmaceuticals would acquire Applied Therapeutics; the two companies are described as separate entities owned by Cycle Group Holdings.
The FDA reviewed the New Drug Application for govorestat in Classical Galactosemia and issued a Complete Response Letter, indicating additional information was needed before approval; the company said the decision was not based on new safety concerns.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Applied Therapeuticsappliedtherapeutics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Applied Therapeutics do?
- Biopharmaceutical company developing govorestat and other aldose reductase inhibitors for rare diseases such as galactosemia.
- Who founded Applied Therapeutics?
- Applied Therapeutics was founded by Shoshana Shendelman in 2016.
- Who are Applied Therapeutics's investors?
- Applied Therapeutics's investors include Evolution VC Partners, Alexandria, Venrock Healthcare Capital Partners.
- How much funding has Applied Therapeutics raised?
- Applied Therapeutics has disclosed $189.2M raised across 6 rounds.
- Where is Applied Therapeutics headquartered?
- Applied Therapeutics is headquartered in New York, US.